In the phase I first-in-human study in hematologic malignancies (waveLINE-001), the ROR1-targeting antibody–drug conjugate zilovertamab vedotin showed promising activity and manageable safety in R/R DLBC. The gene discussed is ROR1; the disease is hematologic disorder.